- In December 2024, Humanetics Corporation secured an additional USD 5 million in funding from the U.S. Department of Defense to support the development of BIO 300, a radiation countermeasure intended for prophylactic use. BIO 300 is being designed to protect military personnel and first responders from radiation exposure, underscoring Humanetics' role in advancing medical preparedness for radiological emergencies. The company aims to pursue Emergency Use Authorization (EUA) to fast-track availability of this critical drug in high-risk scenarios
- In November 2024, HOPO Therapeutics received up to USD 226 million in project funding from BARDA to develop HOPO‑101, the first oral drug candidate for radiation and heavy metal exposure. This funding milestone represents a major step in expanding oral, easy-to-distribute medical countermeasures for nuclear events and radiological attacks, supporting HOPO’s vision of accessible treatments for civilian and defense use
- In October 2024, Synedgen, Inc. announced a partnership with BARDA to accelerate the development of MIIST305, a novel oral therapy to treat Gastrointestinal Acute Radiation Syndrome (GI-ARS). The collaboration reflects BARDA’s focus on expanding the stockpile of next-generation radiation injury drugs with improved administration and storage profiles for national emergency response systems
- In September 2024, Chrysalis BioTherapeutics entered a preclinical evaluation agreement with NIAID to test its drug Chrysalin for cutaneous radiation injuries. The peptide-based therapy is designed to speed up tissue regeneration and wound healing after radiation burns. This move signals a shift toward regenerative approaches in radiation injury management, especially for civilian mass casualty settings
- In August 2024, Tonix Pharmaceuticals announced advancement of its TNX‑801 and TNX‑701 compounds, which are being explored as medical countermeasures for radiation exposure and smallpox. Tonix is actively engaging in federal collaborations to accelerate regulatory pathways and deployment in public health emergency contexts
